The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: an evaluation using interrupted time series analysis.

Benjamin DanielsAndrea L SchafferNicholas A BuckleyClaudia BrunoMin JunSallie-Anne PearsonHelga Zoega

Published in: Pharmacoepidemiology and drug safety (2021)

Tightened prescribing restrictions had an immediate and sustained impact on PPI use in Australia, with decreased high strength use and increased low strength use. Some patients likely switched to private market prescriptions for standard strength PPI, given the observed patterns in total volume sold/dispensed. This article is protected by copyright. All rights reserved.

Keyphrases

primary care
end stage renal disease
ejection fraction
health insurance
newly diagnosed
chronic kidney disease
healthcare
peritoneal dialysis
protein protein
adverse drug
patient reported outcomes